

## CD33 antibody [WM53]

**Cat. No. GTX00477**

<b>Host</b>	Mouse
<b>Clonality</b>	Monoclonal
<b>Isotype</b>	IgG1
<b>Applications</b>	WB, ICC/IF, IHC-Fr, FCM, IP, MS
<b>Reactivity</b>	Human, Primate

Package

100 µg

## PRODUCT

## Summary

CD33, also known as Siglec-3 or gp67, is a 67 kDa glycosylated cell surface receptor that mediates cell-cell interactions and maintains immune cells in a resting state. Although CD33 is found on some lymphoid subsets, it is highly expressed on myeloid lineage cells, and is commonly used for the diagnosis of acute myeloid leukemia (AML). CD33 is an established target for therapy, with CD33-positive blasts detected in almost 90 percent of patients presenting with AML.

## Applications

## Application Note

\*Optimal dilutions/concentrations should be determined by the researcher.

Suggested dilution	Recommended dilution
WB	Assay dependent
ICC/IF	Assay dependent
IHC-Fr	Assay dependent
FCM	Assay dependent
IP	Assay dependent
MS	Assay dependent

Not tested in other applications.

**Calculated MW** 40 kDa. ([Note](#))

## Properties

<b>Form</b>	Liquid
<b>Buffer</b>	PBS
<b>Preservative</b>	15mM Sodium azide
<b>Storage</b>	Store as concentrated solution. Centrifuge briefly prior to opening vial. Store at 4°C. DO NOT FREEZE.
<b>Concentration</b>	1 mg/ml (Please refer to the vial label for the specific concentration.)
<b>Immunogen</b>	Human AML cells



For full product information, images and publications, please visit our [website](#).

**Purification** Protein A purified


**Conjugation** Unconjugated

**Note**

For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.

Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.

**DATA IMAGES**



**GTX00477 FCM Image**

FACS analysis of human peripheral blood using GTX00477 CD33 antibody [WM53].



For full product information, images and publications, please visit our [website](#).